Phase III VERITAC-2 trial results show vepdegestrant significantly improved progression-free survivalcompared to fulvestrant ...

Arvinas (ARVN) stock faces a downgrade after underwhelming trial data for breast cancer drug vepdegestrant developed with ...

BMO Capital analyst Etzer Darout lowered the firm’s price target on Arvinas (ARVN) to $20 from $82 and keeps an Outperform rating on the ...

Pfizer (NYSE:PFE) stock and Arvinas (NASDAQ:ARVN) stock slip in reaction to mixed Phase 3 data for their breast cancer drug vepdegestrant. Read more here.

Vepdegestrant is a novel proteolysis targeting chimera protein degrader designed to target and degrade the estrogen receptor.

Arvinas (ARVN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in ...

BofA lowered the firm’s price target on Arvinas (ARVN) to $28 from $54 and keeps a Buy rating on the shares after the Phase 3 VERITAC-2 trial ...

Arvinas stock plummets 53% on mixed data from phase III metastatic breast cancer study on lead pipeline candidate, vepdegestrant.

VERITAC-2 achieved its primary endpoint in the estrogen receptor 1-mutant population, demonstrating statistically significant and clinically meaningful ...

Arvinas and Pfizer will share the costs and profits of the development and commercialization of vepdegestrant, which has ...